Akari Therapeutics Plc earnings releases AKTX

Annual Quarterly

Akari Therapeutics Plc last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of $0.00. It usually reports 1–50 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 1–50 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 13, 2026
44 days after quarter end
Q2 FY2026
ended Jun 30, 2026
—
-5
-153.7%
0.00
Apr 16, 2025
16 days after quarter end
Q1 FY2025
ended Mar 31, 2025
—
-4
+33.4%
0.00
Aug 19, 2024
50 days after quarter end
—
ended Jun 30, 2024
—
—
—
Apr 1, 2024
1 days after quarter end
—
ended Mar 31, 2024
—
—
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AKTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
United Kingdom
Headquarters
Tampa, FL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1541157
Former names
Celsus Therapeutics Plc. (until Sep 15, 2015); Morria Biopharmaceuticals PLC (until Jun 20, 2013)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.